Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Melinda N. Tea"'
Autor:
Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P.-S. Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 1-11 (2022)
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients, this haematological mal
Externí odkaz:
https://doaj.org/article/f5e0bdd9d3004cfdbf70bbe296a47fe3
Autor:
Mariana Oksdath Mansilla, Camilo Salazar-Hernandez, Sally L. Perrin, Kaitlin G. Scheer, Gökhan Cildir, John Toubia, Kristyna Sedivakova, Melinda N. Tea, Sakthi Lenin, Elise Ponthier, Erica C. F. Yeo, Vinay Tergaonkar, Santosh Poonnoose, Rebecca J. Ormsby, Stuart M. Pitson, Michael P. Brown, Lisa M. Ebert, Guillermo A. Gomez
Publikováno v:
BMC Biomedical Engineering, Vol 3, Iss 1, Pp 1-14 (2021)
Abstract Background Organoids are a reliable model used in the study of human brain development and under pathological conditions. However, current methods for brain organoid culture generate tissues that range from 0.5 to 2 mm of size, which need to
Externí odkaz:
https://doaj.org/article/bb2b7d7fa4cd4072a534f3d2e82c57e7
Autor:
Paris M. Kollis, Lisa M. Ebert, John Toubia, Cameron R. Bastow, Rebecca J. Ormsby, Santosh I. Poonnoose, Sakthi Lenin, Melinda N. Tea, Stuart M. Pitson, Guillermo A. Gomez, Michael P. Brown, Tessa Gargett
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades. T-cell-based immunotherapies such as immune-checkpoint inhibitors and chimeric antigen
Externí odkaz:
https://doaj.org/article/acdaa2cfb7ca4c1c9e49370d3b46e739
Autor:
Sakthi Lenin, Elise Ponthier, Kaitlin G. Scheer, Erica C. F. Yeo, Melinda N. Tea, Lisa M. Ebert, Mariana Oksdath Mansilla, Santosh Poonnoose, Ulrich Baumgartner, Bryan W. Day, Rebecca J. Ormsby, Stuart M. Pitson, Guillermo A. Gomez
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 9, p 4322 (2021)
Glioblastoma is one of the most common and lethal types of primary brain tumor. Despite aggressive treatment with chemotherapy and radiotherapy, tumor recurrence within 6–9 months is common. To overcome this, more effective therapies targeting canc
Externí odkaz:
https://doaj.org/article/55bd8747d563491eb5b4e5dad723bbb9
Autor:
Wenbo Yu, Nga TH Truong, Ruhi Polara, Tessa Gargett, Melinda N Tea, Stuart M Pitson, Michaelia P Cockshell, Claudine S Bonder, Lisa M Ebert, Michael P Brown
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Objectives CAR‐T cells are being investigated as a novel immunotherapy for glioblastoma, but clinical success has been limited. We recently described fibroblast activation protein (FAP) as an ideal target antigen for glioblastoma immunothe
Externí odkaz:
https://doaj.org/article/015396e342d8443aa4091f21f509b391
Autor:
Briony L. Gliddon, Craig T. Wallington-Beddoe, Manjun Li, Darren J. Creek, Melissa R. Pitman, Melinda N. Tea, Paul Wang, Dovile Anderson, John Toubia, Melissa K. Bennett, Robert Z. Orlowski, Stuart M. Pitson, Jason A. Powell
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 1-11 (2022)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Refereed/Peer-reviewed The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients,
Autor:
Natasha T. Pyne, Marina Kochetkova, Andrew I. Webb, Alexander C. Lewis, Kendelle J. Murphy, Paul Timpson, Paul A.B. Moretti, Melinda N. Tea, Stuart M. Pitson, Angel F. Lopez, Sarah T. Boyle, Natasha Kolesnikoff, Vinay Tergaonkar, Jasreen Kular, Robert Whitfield, Jarrod J. Sandow, Valentina Poltavets, Michael S. Samuel
Publikováno v:
Nature Cell Biology. 22:882-895
It is well accepted that cancers co-opt the microenvironment for their growth. However, the molecular mechanisms that underlie cancer-microenvironment interactions are still poorly defined. Here, we show that Rho-associated kinase (ROCK) in the mamma
Autor:
Alexander C. Lewis, Victoria S. Pope, Melinda N. Tea, Manjun Li, Gus O. Nwosu, Thao M. Nguyen, Craig T. Wallington-Beddoe, Paul A. B. Moretti, Dovile Anderson, Darren J. Creek, Maurizio Costabile, Saira R. Ali, Chloe A. L. Thompson-Peach, B. Kate Dredge, Andrew G. Bert, Gregory J. Goodall, Paul G. Ekert, Anna L. Brown, Richard D’Andrea, Nirmal Robinson, Melissa R. Pitman, Daniel Thomas, David M. Ross, Briony L. Gliddon, Jason A. Powell, Stuart M. Pitson
Inducing cell death by the sphingolipid ceramide is a potential anticancer strategy, but the underlying mechanisms remain poorly defined. In this study, triggering an accumulation of ceramide in acute myeloid leukemia (AML) cells by inhibition of sph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed8fbe2daf653ebbee791ab6b83276b
https://hdl.handle.net/11541.2/31406
https://hdl.handle.net/11541.2/31406
Autor:
Tessa Gargett, Lisa M Ebert, Nga T H Truong, Paris M Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C F Yeo, Nicole L Wittwer, Briony L Gliddon, Melinda N Tea, Rebecca Ormsby, Santosh Poonnoose, Jake Nowicki, Orazio Vittorio, David S Ziegler, Stuart M Pitson, Michael P Brown
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005187
BackgroundAggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the potential for severe toxicity. Effective treatments for primary brain tumors are limited, a
Autor:
Lisa M. Ebert, Sakthi Lenin, Santosh Poonnoose, Ulrich Baumgartner, Stuart M. Pitson, Melinda N Tea, Erica C. F. Yeo, Kaitlin G. Scheer, Guillermo A. Gomez, Elise Ponthier, Rebecca J. Ormsby, Bryan W. Day, Mariana Oksdath Mansilla
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 4322, p 4322 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 9
International Journal of Molecular Sciences
Volume 22
Issue 9
Glioblastoma is one of the most common and lethal types of primary brain tumor. Despite aggressive treatment with chemotherapy and radiotherapy, tumor recurrence within 6–9 months is common. To overcome this, more effective therapies targeting canc